As the first psychedelic-assisted therapies head towards potential regulatory approvals, we’re becoming increasingly focused on the challenges that drug developers, providers and patients may face
Department of Regulatory Agencies Stakeholder Engagement Meeting: March 8th, 2024 On Friday, March 8th, the Department of Regulatory Agencies (“DORA”) held its first Stakeholder Engagement
Psychedelic drug developer Gilgamesh Pharmaceuticals has scooped a grant worth $14m from the National Institute on Drug Abuse (NIDA) to develop its ibogaine analog, GM-3009,
Today, psychedelic drug developer Cybin announced that it has received breakthrough therapy designation for CYB003, its deuterated psilocybin analog candidate under development for major depressive
Hardman: I want to pick up on something that you started talking about: the corporatisation of psychedelics, which is obviously a big topic. I don’t
Psychedelic drug developer MindMed today announced that the FDA has granted breakthrough therapy designation to its LSD candidate (MM120) for the treatment of generalised anxiety
Featured content in this Issue: Fluence and UPRA Team Up to Bring Psychedelic Therapy Training to Ukraine MindBio’s Small Open Label Microdosing Study Shows Promise
One of the at-home ketamine industry’s biggest boosters has turned bearish, calling for caution among patients and providers and withdrawing his endorsement of the practice.
Featured content in this Issue: Incannex Shares Topline Results from Phase 2a Study of Psilocybin for Generalised Anxiety Disorder An Uptick in Psilocybin-Related Poison Centre
Supervised Practice (Practicum) Facilitator training programs must require students to complete supervised practice (practicum) training which provides an opportunity to experience, facilitate and observe the